Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Short-term Investments (2016 - 2018)

Historic Short-term Investments for Angiodynamics (ANGO) over the last 10 years, with Q4 2018 value amounting to $1.3 million.

  • Angiodynamics' Short-term Investments rose 714.29% to $1.3 million in Q4 2018 from the same period last year, while for Nov 2018 it was $1.3 million, marking a year-over-year increase of 714.29%. This contributed to the annual value of $1.3 million for FY2018, which is 839.51% up from last year.
  • According to the latest figures from Q4 2018, Angiodynamics' Short-term Investments is $1.3 million, which was up 714.29% from $1.3 million recorded in Q3 2018.
  • Angiodynamics' Short-term Investments' 5-year high stood at $1.8 million during Q1 2014, with a 5-year trough of $1.2 million in Q4 2016.
  • In the last 5 years, Angiodynamics' Short-term Investments had a median value of $1.6 million in 2015 and averaged $1.5 million.
  • As far as peak fluctuations go, Angiodynamics' Short-term Investments crashed by 2779.11% in 2017, and later soared by 1111.11% in 2018.
  • Over the past 5 years, Angiodynamics' Short-term Investments (Quarter) stood at $1.7 million in 2014, then fell by 3.47% to $1.6 million in 2015, then decreased by 26.6% to $1.2 million in 2016, then increased by 4.74% to $1.3 million in 2017, then increased by 7.14% to $1.3 million in 2018.
  • Its Short-term Investments stands at $1.3 million for Q4 2018, versus $1.3 million for Q3 2018 and $1.3 million for Q2 2018.